How DeLauro Set The Agenda: Principal Avandia Players Not Invited To Hearing
Executive Summary
The decision of Rep. Rosa DeLauro, D-Conn., not to invite Avandia maker GlaxoSmithKline or FDA to an April 28 House Appropriations subcommittee hearing on the drug's safety illustrates some of the challenges that she may face if she moves to overhaul the agency's review and surveillance procedures.